Development of a CHO cell line for stable production of recombinant antibodies against human MMP9

Multi-scale design and optimization of antibody production via flexible nets

Antibodies are therapeutic proteins with many applications in medicine, such as treating viral infections, different types of cancer, and common diseases such as psoriasis and multiple sclerosis. Chinese Hamster Ovary (CHO) cells are the most widely used cells for antibody production due to their well-established use and favorable features. However, the current design of antibody production systems often relies on a "trial and error" approach to manipulate CHO cells. This approach is time-consuming and costly, and can lead to suboptimal process performance. The use of mathematical models has the potential to greatly accelerate and improve the design and optimization of antibody production. Starting from a systematic and formal approach, the aim is to achieve an automatic design of the whole process that allows optimal productivity to be reached. To this end, we develop mathematical models and methods for the design and optimization of antibody manufacturing systems. The mathematical models are based on Flexible Nets (FNs), a modeling formalism that accommodates uncertain parameters and nonlinear dynamics. FNs enable the development of comprehensive models that encompass both the metabolic network of CHO cells and the dynamics of the bioreactor in which the cells are cultured. Thus, by integrating macroscopic variables (e.g. dilution rate, substrate concentration, cell density, etc.) with microscopic variables (such as intracellular metabolic fluxes), our model represents a multi-scale system and facilitates global optimization.

Convenient production of a novel recombinant antibody against periodontitis biomarker S100A8

S100A8 serves as a biomarker for periodontitis and is involved in inflammatory processes, making its detection highly important. In this study, we produced recombinant 5A11 (r5A11) through mammalian cell culture. By employing a three-step process of transfection, suspension cell culture, and purification, we conveniently produced r5A11 with high yield and purity. The limit of detection for the r5A11-based immunoassay was 1.7 ± 0.2 × 10-1 ng/mL, which was higher than that of the commercially available anti-S100A8 antibody. These findings suggest the potential use of this novel antibody in various research applications and practical approaches for simple and sensitive S100A8 detection.

An optofluidic platform for cell-counting applications

Cell-counting is critical for a wide range of applications, e.g., life sciences, medicine, or pharmacology. Hemocytometry is a classical method that requires manual counting of cells under a microscope. This methodology is low-cost but manual counting is slow, and the test accuracy is limited by the operator experience. Accuracy and throughput of such application could be improved with the use of automated cell-counting devices. Possessing the ability of recording and processing cell images, devices employing these technologies could dramatically improve the accuracy of the counting results. However, accuracy of these devices still requires further improvement as the counting results rely only on 100-200 cells. Furthermore, the test cost of these devices increases due to the need for a counting chamber or consumables compatible with their hardware settings. Herein, in order to address these drawbacks, we introduced an optofluidic cell-counting platform that could scan more than 2000 cells, which dramatically improves the test accuracy. Our technology could yield an error rate below 1% for cell viability, and below 5% for cell concentration. The platform could deliver the count results within only ∼1 minute, including sample loading, autofocusing, recording images, and image processing. The presented platform also benefits from a built-in fluidic component that eliminates the need for an external counting chamber, and allows fully automated sample loading and self-cleaning modality compatible with any solutions that are typically used for cell-counting tests. Providing an easy-to-use and rapid feature from sample loading to image analyses, our optofluidic platform could be a critical asset for accurate and low cost cell-counting applications.

Expression of mammalian proteins for diagnostics and therapeutics: a review

BACKGROUND

Antibodies have proven to be remarkably successful for biomedical applications. They play important roles in epidemiology and medicine from diagnostics of diseases to therapeutics, treating diseases from incessant chronic diseases such as rheumatology to pandemic outbreaks. With no end in sight for the demand for antibody products, optimizations and new techniques must be expanded to accommodate this.

METHODS AND RESULTS

This review discusses optimizations and techniques for antibody production through choice of discovery platforms, expression systems, cell culture mediums, and other strategies to increase expression yield. Each system has its own merits and demerits, and the strategy chosen is critical in addressing various biological aspects.

CONCLUSIONS

There is still insufficient evidence to validate the efficacy of some of these techniques, and further research is needed to consolidate these industrial production systems. There is no doubt that more strategies, systems, and pipelines will contribute to enhance biopharmaceutical production.